The Effect of Simvastatin on Serum Level of Matrix Metalloprotease-1,Matrix Metalloprotease-9 and Tissue Inhibitors of Matrix Metalloproteinase-1 in Patients with Acute Coronary Syndromes

Objective To observe the effect of simvastatin of serun levels of matrix metalloprotease-9 (MMP-1?MMP-9) and tissue inhibitors of matris metalloproteinase-1 (TIMP-1) in patients with acute coronary syndromes(ACS).Methods 90 patients with coronary heart disease were studied. Among them, there were 30 patients with stable angina pectoris(SAP) and 60 patients with ACS. At the same time, 30 cases of age matched healthy individuals were selected as a control.54 patients with ACS were randomly divided into two groups:Simvastatin treatment group and regular treatment group. The serum level of MMP-1?MMP-9and TIMP-1 were compared among all groups.Results There was a significant difference in serum level of MMP-1?MMP-9 and TIMP-1 among SAP group, ACS group and control group.The serum level of MMP-1?MMP-9 and TIMP-1 were different between simanastatin treatment group and regular treatment group after treatment.Conclusions Plaque disruption may be related to the increased serum level of MMP-1?MMP-9 and the decreased serum level of TIMP-1. Simavastatin can decrease serum level of MMP-1?MMP-9 and increase serum level of TIMP-1 in patients with ACS,and int may have a beneficial effect on steadying the plaque.